Market Research Logo

Country Overviews Market Research Reports & Industry Analysis

Find the information you need on global healthcare in country overviews. Our collection of market research reports provides insights into product and market trends, analysis, opportunities, projections, sales and marketing strategies with specifics on market share, segmentation, size and growth by country.
...Show More ...Show Less

Country Overviews Industry Research & Market Reports

  • Czech Republic Pharmaceuticals & Healthcare Q3 2019

    ... for higher-value medicines and a robust regulatory environment. We note, however, that a lack ofgeneric medicine uptake raises significant questions around market sustainability and poses downside risks of moreaggressive cost-containment measures in the long term. Read More

  • Denmark Pharmaceuticals & Healthcare Q3 2019

    ... products, increasing multinationals' opportunities for quickerearnings. Long-term growth in the Danish pharmaceutical and healthcare market will be supported by an expanding and ageing andpopulation as well as a growing chronic disease burden, placing more demand ... Read More

  • Kazakhstan Pharmaceuticals & Healthcare Q3 2019

    ... rapid pace of development ofregulatory policies. Although the implementation of the unified medicine price policy may result in lower prices for some drugs inthe short term, we believe that the increased patient access will bode ... Read More

  • Singapore Pharmaceuticals & Healthcare Q3 2019

    ... by an ageingpopulation and high disease burden. Although this demographic profile is favourable to innovative drugmakers, patented drug saleswill be limited by the government’s drug pricing and reimbursement policies as well as other cost-containment measures. Read More

  • Greece Pharmaceuticals & Healthcare Q3 2019

    ... resulting in high levels of debt. Medicine sales will remain on a low growthtrajectory, albeit now positive, due to restrictive public funding. Repressive government policy, including aggressive pricing, highclawback and rebates, will continue to repress ... Read More

  • Costa Rica Pharmaceuticals & Healthcare Q3 2019

    ... treatment and the gradual launch of new therapies will support this trend.Costa Rica will continue to represent a stable operating environment in Latin America although the relatively small market size willcontinue to weigh on the ... Read More

  • Croatia Pharmaceuticals & Healthcare Q3 2019

    ... OTC market will experience a one-off negative hit to growth in2019, which will filter through to slightly repressed overall pharmaceutical sales growth. Our outlook for the Croatianpharmaceutical market over the longer term remains the same; ... Read More

  • Panama Pharmaceuticals & Healthcare Q3 2019

    ... recurrent medicine shortages and risingmedicine prices, the incoming government will likely place particular attention on these and other issues arising in part from thelack of a unified public health system and inefficient regulatory processes. Panama’s ... Read More

  • Sweden Pharmaceuticals & Healthcare Q3 2019

    ... regional standards and aggressive drug pricingpolicies will continue to weigh on the market potential. The government will remain committed towards supporting health careinnovations and personalised medical treatment development, while pharmaceutical exports will continue to grow. Read More

  • Bahrain Pharmaceuticals & Healthcare Q3 2019

    ... the dominance of larger players in the Gulf region will derail anymeaningful investment away from Bahrain's underdeveloped market. Furthermore, we believe that the measures proposed underthe Bahrain’s new National Employment Programme (NEP), if approved by ... Read More

  • Bangladesh Pharmaceuticals & Healthcare Q3 2019

    ... rising demand for chronic disease treatment will create renewedopportunities for drugmakers. Bangladesh’s pharmaceutical products, which currently account for a large percentage of thedomestic market, will continue to expand its export footprint into key global markets. Read More

  • Health Care Sector

    ... facilities. Major companies include Ascension Health, HCA, Kaiser Permanente, and Tenet Healthcare (all based in the US), as well as Fresenius (Germany), National Hospital Organization (Japan), and Ramsay Health Care (Australia). COMPETITIVE LANDSCAPE Health care ... Read More

  • India Pharmaceuticals & Healthcare Q3 2019

    ... support robust growth of its pharmaceutical and healthcare spending. In thecoming years, we believe growth in the market will be boosted by an increase in healthcare funding as well as the government’slong-term health development plan. Read More

  • Bulgaria Pharmaceuticals & Healthcare Q2 2019

    ... to improve the quality and capacity of Bulgaria's healthsystem. However, recent protests over the lack of transparency on the setting of pharmaceutical contracts and the failure tonormalise the drugs supply highlight the growing need for ... Read More

  • El Salvador Pharmaceuticals & Healthcare Q2 2019

    ... slow but steady improvement to pharmaceutical production infrastructureand intellectual property provisions. However, owing to a persistent lack of coordination, underdeveloped informationsystems and financial instability, the health sector has been unable to exploit the country's abundant ... Read More

  • Estonia Pharmaceuticals & Healthcare Q2 2019

    ... which will repress long-term opportunities.Nonetheless, we expect the government’s increased healthcare funding over the coming years - following historically inadequatelevels – will improve patient access to healthcare and boost drugmaker prospects in the short and ... Read More

  • Slovakia Pharmaceuticals & Healthcare Q2 2019

    ... while corruption and the use of bribes seemsto be on the decline, the Slovak healthcare system is still struggling with certain aspects, including the provision of adequatefunding and keeping the lid on patient co-payment increases. Read More

  • Nicaragua Pharmaceuticals & Healthcare Q2 2019

    ... and long-term, the sector will remain heavily underfunded. Withthe government cutting funding for numerous healthcare projects along with the mass dismissals of medical professionals inretaliation to wide spread unrest in 2018, patient access to health ... Read More

  • Europe Pharmaceuticals & Healthcare Q2 2019

    ... to region-specific trends. Themore developed Western markets will continue to be favoured by innovative drugmakers due to stronger regulatory oversight andgreater purchasing power, although growth in these markets will be suppressed by aggressive cost-containment. Revenue ... Read More

  • Ghana Pharmaceuticals & Healthcare Q2 2019

    ... has led to difficulties doingbusiness, including high operational costs for foreign companies. While Ghana is positioned as one of the more attractivepharmaceutical markets for multinational firms on a regional basis, generic products will maintain a ... Read More

  • Guatemala Pharmaceuticals & Healthcare Q2 2019

    ... constraints will remain a recurrent issue. This will bepartially addressed by new healthcare infrastructure projects announced by the social security institute. Government steps towardsunifying the health system will progress at a gradual pace, limiting significant ... Read More

  • Kenya Pharmaceuticals & Healthcare Q2 2019

    ... access to and qualityof services. Additionally, wealthier urban pockets represent a potential market for multinationals that offer high-value medicines .However, per capita spending on both pharmaceuticals and healthcare remains modest in comparison with similar Asian ... Read More

  • Netherlands Pharmaceuticals & Healthcare Q2 2019

    ... under the Medicines Prices Act. We expect innovative drug sales will continueto decline in the short term, with growth in this sub-sector returning over the longer term as the population ages and chronicillnesses rise. However, ... Read More

  • Asia Pharmaceuticals & Healthcare Q2 2019

    ... However, these markets will no longer providesignificant revenue growth due to aggressive cost containment. Instead, growth opportunities will be plentiful in emerging markets.We note that due to continued regulatory challenges and a growing focus on ... Read More

  • Brazil Pharmaceuticals & Healthcare Q2 2019

    ... remain a highly challenging market. A restriction onpublic healthcare expenditure will place additional pressures on medicine prices while schemes to control prices and boost localcapacity will further dissuade foreign investment. Of the four BRICs markets, ... Read More

< prev 1 3 4 5 6 7 8 9 10

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog